GBT
NTLA icon

Grove Bank & Trust’s Intellia Therapeutics NTLA Stock Holding History

Grove Bank & Trust’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-126
Closed -$3.98K – 661
2023
Q3 		$3.98K Buy
+126
New +$4.89K ﹤0.01% 595

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Grove Bank & Trust's NTLA Position: Q4 2023 in Review

Grove Bank & Trust sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 126 shares — an estimated $3.98K sold.

Grove Bank & Trust first reported a position in NTLA in Q3 2023 and held it in 1 quarter. The position peaked at $3.98K in Q3 2023. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Grove Bank & Trust reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 126 Intellia Therapeutics shares in Q4 2023, an estimated $3.98K.
  • Grove Bank & Trust first reported a position in Intellia Therapeutics in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's Intellia Therapeutics position peaked at $3.98K in Q3 2023.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.